Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial

Circulating tumour necrosis factor is highly correlated with brainstem serotonin transporter availability in humans

“…Secondly, this population gave us the ideal opportunity to explore the effect of TNF antagonism on 5-HTT. Earlier research in this population has shown that TNF antagonism was associated with an antidepressant effect that was independent of disease improvement (Gelfand et al, 2008;Krishnan et al, 2007;Langley et al, 2010;Tyring et al, 2006). Consistent with previous studies, TNF-α explained only around 3% of and brain stem 5-HTT availability explained only around 7% variance in depression severity (Gryglewski et al, 2014;Valkanova et al, 2013).…”

Impact and management of depression in psoriasis patients

“…Etanercept reduced depression 29% in psoriasis patients with minimal depression [24]. Ustekinumab reduced depression 55%; 27% and 12% of patients reported depression before and after treatment, respectively [25]. Adalimumab reduced depression 18.5% [26].…”

Formulary Review of 2 New Biologic Agents: Tocilizumab for Rheumatoid Arthritis and Ustekinumab for Plaque Psoriasis

“…27 The analysis used the Hospital Anxiety and Depression Scale (HADS) to assess patients' mental health in the study. A score of 8 or greater on the HADS scale indicated presence of depression or anxiety, respectively.…”